X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs LUPIN LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE LUPIN LTD CADILA HEALTHCARE/
LUPIN LTD
 
P/E (TTM) x 19.3 28.5 67.9% View Chart
P/BV x 4.6 3.0 153.8% View Chart
Dividend Yield % 0.9 0.6 160.4%  

Financials

 CADILA HEALTHCARE   LUPIN LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
LUPIN LTD
Mar-18
CADILA HEALTHCARE/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs5581,465 38.1%   
Low Rs362727 49.7%   
Sales per share (Unadj.) Rs116.3349.6 33.3%  
Earnings per share (Unadj.) Rs17.95.6 321.5%  
Cash flow per share (Unadj.) Rs23.129.6 78.2%  
Dividends per share (Unadj.) Rs3.505.00 70.0%  
Dividend yield (eoy) %0.80.5 166.9%  
Book value per share (Unadj.) Rs85.4300.3 28.4%  
Shares outstanding (eoy) m1,023.74452.08 226.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.03.1 126.1%   
Avg P/E ratio x25.7197.2 13.0%  
P/CF ratio (eoy) x19.937.1 53.6%  
Price / Book Value ratio x5.43.6 147.5%  
Dividend payout %19.690.0 21.8%   
Avg Mkt Cap Rs m470,664495,502 95.0%   
No. of employees `00011.817.0 69.4%   
Total wages/salary Rs m18,54528,647 64.7%   
Avg. sales/employee Rs Th10,072.79,273.6 108.6%   
Avg. wages/employee Rs Th1,569.11,681.0 93.3%   
Avg. net profit/employee Rs Th1,547.7147.4 1,049.7%   
INCOME DATA
Net Sales Rs m119,049158,042 75.3%  
Other income Rs m1,1321,504 75.3%   
Total revenues Rs m120,181159,545 75.3%   
Gross profit Rs m28,47531,475 90.5%  
Depreciation Rs m5,38810,859 49.6%   
Interest Rs m9112,044 44.6%   
Profit before tax Rs m23,30820,076 116.1%   
Minority Interest Rs m628-71 -885.8%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m5,6442,885 195.7%   
Profit after tax Rs m18,2922,513 728.0%  
Gross profit margin %23.919.9 120.1%  
Effective tax rate %24.214.4 168.5%   
Net profit margin %15.41.6 966.5%  
BALANCE SHEET DATA
Current assets Rs m82,005122,095 67.2%   
Current liabilities Rs m60,72050,956 119.2%   
Net working cap to sales %17.945.0 39.7%  
Current ratio x1.42.4 56.4%  
Inventory Days Days7385 86.5%  
Debtors Days Days98120 82.0%  
Net fixed assets Rs m83,703129,876 64.4%   
Share capital Rs m1,024904 113.2%   
"Free" reserves Rs m86,421134,866 64.1%   
Net worth Rs m87,445135,771 64.4%   
Long term debt Rs m25,55164,245 39.8%   
Total assets Rs m180,653263,054 68.7%  
Interest coverage x26.610.8 245.6%   
Debt to equity ratio x0.30.5 61.8%  
Sales to assets ratio x0.70.6 109.7%   
Return on assets %10.61.7 613.7%  
Return on equity %20.91.9 1,130.3%  
Return on capital %22.03.7 591.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68353,141 80.3%   
Fx outflow Rs m11,24219,335 58.1%   
Net fx Rs m31,44133,807 93.0%   
CASH FLOW
From Operations Rs m9,19317,512 52.5%  
From Investments Rs m-9,737-14,073 69.2%  
From Financial Activity Rs m515-14,921 -3.5%  
Net Cashflow Rs m-29-11,482 0.3%  

Share Holding

Indian Promoters % 74.8 46.6 160.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.3 11.3 73.5%  
FIIs % 5.9 31.9 18.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.1 108.9%  
Shareholders   44,069 98,259 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Recovers after Crashing Over 1000 Points; DHFL Tanks 50%(01:30 pm)

Stock markets in India plunged in the afternoon session today. The BSE Sensex recovered after tanking 1,000 points in intra-day deals.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 21, 2018 02:57 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - TTK HEALTHCARE COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS